Patents by Inventor Michal Harel

Michal Harel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250118405
    Abstract: Methods of predicting response of a subject suffering from a disease to a therapy, comprising calculating a resistance score for factors expressed by the subject, classifying a factor as a resistance-associated factor based on the resistance score, wherein a number of resistance-associated factors above a predetermined threshold indicates a subject is predicted to be resistant to the therapy, are provided. Methods of predicting response based on the number of resistance-associated factors and at least one clinical parameter are also provided.
    Type: Application
    Filed: August 11, 2022
    Publication date: April 10, 2025
    Inventors: Coren LAHAV, Itamar SELA, Yehonatan ELON, Michal HAREL, Eyal JACOB
  • Publication number: 20240153609
    Abstract: Methods of selecting a therapeutic agent to treat a cancer in a subject comprising receiving a plurality of protein data element values representing levels of the proteins in a biological sample from the subject, classifying each protein as a member of a process class, for each process class calculating a process score that represents the prominence of the process class to cancer treatment resistance and selecting at least one therapeutic agent that targets a selected process based on the process score. Systems for selecting a therapeutic agent are also provided.
    Type: Application
    Filed: January 11, 2024
    Publication date: May 9, 2024
    Inventors: Eyal JACOB, Michal HAREL, Ben YELLIN, Coren LAHAV, Itamar SELA, Yehonatan ELON
  • Patent number: 11908560
    Abstract: Methods of selecting a therapeutic agent to treat a cancer in a subject comprising receiving a plurality of protein data element values representing levels of the proteins in a biological sample from the subject, classifying each protein as a member of a process class, for each process class calculating a process score that represents the prominence of the process class to cancer treatment resistance and selecting at least one therapeutic agent that targets a selected process based on the process score. Systems for selecting a therapeutic agent are also provided.
    Type: Grant
    Filed: August 11, 2022
    Date of Patent: February 20, 2024
    Assignee: ONCOHOST LTD.
    Inventors: Eyal Jacob, Michal Harel, Ben Yellin, Coren Lahav, Itamar Sela, Yehonatan Elon
  • Publication number: 20230266326
    Abstract: Methods of determining a therapeutic response to immunotherapy in a subject suffering from lung cancer are provided. Kits for use in determining a therapeutic response to immunotherapy are also provided.
    Type: Application
    Filed: June 21, 2021
    Publication date: August 24, 2023
    Inventors: Coren LAHAV, Michal HAREL, Eran ISSLER
  • Publication number: 20230084735
    Abstract: Methods of selecting a therapeutic agent to treat a cancer in a subject comprising receiving a plurality of protein data element values representing levels of the proteins in a biological sample from the subject, classifying each protein as a member of a process class, for each process class calculating a process score that represents the prominence of the process class to cancer treatment resistance and selecting at least one therapeutic agent that targets a selected process based on the process score. Systems for selecting a therapeutic agent are also provided.
    Type: Application
    Filed: August 11, 2022
    Publication date: March 16, 2023
    Inventors: Eyal JACOB, Michal HAREL, Ben YELLIN, Coren LAHAV, Itamar SELA, Yehonatan ELON
  • Publication number: 20230049979
    Abstract: A method comprising receiving, for each of a plurality of subjects having a specified type of disease and receiving a specified therapy for treating the disease, a first biological signature obtained pre-treatment and a second biological signature obtained on-treatment; calculating, for each of the plurality of subjects, a set of values representing a ratio between the first and second biological signatures associated with the respective subject; at a training stage, training a machine learning model on a training set comprising: (i) the calculated sets of values, and (ii) labels associated with an outcome of the specified therapy in each of the subjects; to generate a classifier suitable for predicting a response in a target patient to said specified therapy.
    Type: Application
    Filed: February 7, 2021
    Publication date: February 16, 2023
    Inventors: Eran ISSLER, Michal HAREL, Coren LAHAV, Eyal JACOB, Itamar SELA
  • Patent number: 7855063
    Abstract: A method of identifying a compound capable of correcting an impaired enzymatic activity of a mutant glucocerebrosidase molecule, the method comprising: (a) obtaining a first set of structure coordinates, the first set of structure coordinates defining a 3D structure of a glucocerebrosidase molecule capable of displaying normal enzymatic activity or a portion thereof; (b) computationally generating using the first set of structure coordinates a second set of structure coordinates, the second set of structure coordinates defining a predicted 3D structure of the mutant glucocerebrosidase molecule or a portion thereof; and (c) computationally identifying, using the second set of structure coordinates, a compound capable of interacting with the mutant glucocerebrosidase molecule in such a way as to correct the impaired enzymatic activity thereof, thereby identifying the compound capable of correcting the impaired enzymatic activity of the mutant glucocerebrosidase molecule.
    Type: Grant
    Filed: April 18, 2004
    Date of Patent: December 21, 2010
    Assignee: Yeda Research And Development Co. Ltd.
    Inventors: Anthony Futerman, Joel L. Sussman, Israel Silman, Michal Harel, Hay Dvir, Lilly Toker
  • Publication number: 20070166813
    Abstract: A method of identifying a compound capable of correcting an impaired enzymatic activity of a mutant glucocerebrosidase molecule, the method comprising: (a) obtaining a first set of structure coordinates, the first set of structure coordinates defining a 3D structure of a glucocerebrosidase molecule capable of displaying normal enzymatic activity or a portion thereof; (b) computationally generating using the first set of structure coordinates a second set of structure coordinates, the second set of structure coordinates defining a predicted 3D structure of the mutant glucocerebrosidase molecule or a portion thereof; and (c) computationally identifying, using the second set of structure coordinates, a compound capable of interacting with the mutant glucocerebrosidase molecule in such a way as to correct the impaired enzymatic activity thereof, thereby identifying the compound capable of correcting the impaired enzymatic activity of the mutant glucocerebrosidase molecule.
    Type: Application
    Filed: April 18, 2004
    Publication date: July 19, 2007
    Inventors: Anthony Futerman, Joel Sussman, Israel Silman, Michal Harel, Hay Dvir, Lilly Toker, Swetlana Adamsky